P

Prime Medicine Inc
NASDAQ:PRME

Watchlist Manager
Prime Medicine Inc
NASDAQ:PRME
Watchlist
Price: 2.9 USD 3.94% Market Closed
Market Cap: 380.4m USD
Have any thoughts about
Prime Medicine Inc?
Write Note

Operating Margin
Prime Medicine Inc

-28 286%
Current
-7 859%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-28 286%
=
Operating Profit
-226.3m
/
Revenue
800k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Prime Medicine Inc
NASDAQ:PRME
380.4m USD
-28 286%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-22%
Country US
Market Cap 380.4m USD
Operating Margin
-28 286%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.3B USD
Operating Margin
28%
Country US
Market Cap 141.6B USD
Operating Margin
19%
Country US
Market Cap 115.3B USD
Operating Margin
38%
Country US
Market Cap 102.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.7B AUD
Operating Margin
26%
Country US
Market Cap 77.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36.2B EUR
Operating Margin
-22%
No Stocks Found

Prime Medicine Inc
Glance View

Market Cap
380.4m USD
Industry
Biotechnology

Prime Medicine Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-10-20. Prime Medicine, Inc. is a United States-based biotechnology company. The firm is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The firm's Prime Editing, a transformative technology that addressed the cause of genetic disease. The firm's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.

PRME Intrinsic Value
1.69 USD
Overvaluation 42%
Intrinsic Value
Price
P

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-28 286%
=
Operating Profit
-226.3m
/
Revenue
800k
What is the Operating Margin of Prime Medicine Inc?

Based on Prime Medicine Inc's most recent financial statements, the company has Operating Margin of -28 286%.